Monte Rosa Therapeutics (GLUE) Net Cash Flow (2020 - 2026)

Monte Rosa Therapeutics' Net Cash Flow history runs 7 years deep, the most recent figure standing at $30.0 million for Q1 2026.

• In Q1 2026, Net Cash Flow rose 120.57% year-over-year to $30.0 million; the TTM figure through Mar 2026 stood at $81.4 million (up 483.85% YoY), while the FY2025 annual figure was -$94.3 million, down 197.76% from the prior year.
• Net Cash Flow for Q1 2026 stood at $30.0 million, up from -$78.5 million in the prior quarter.
• The five-year high for Net Cash Flow was $138.9 million in Q3 2025, with the low at -$207.8 million in Q1 2022.
• The 5-year median for Net Cash Flow is -$3.1 million (2023), against an average of -$11.0 million.
• The sharpest annual moves came in 2024 and 2025: Net Cash Flow slumped 816.59% in 2024, then surged 728.35% in 2025.
• Monte Rosa Therapeutics' Net Cash Flow stood at -$57.5 million in 2022, then soared by 220.25% to $69.1 million in 2023, then soared by 42.73% to $98.6 million in 2024, then sank by 179.54% to -$78.5 million in 2025, then jumped by 138.2% to $30.0 million in 2026.
• Business Quant data shows GLUE's Net Cash Flow at $30.0 million in Q1 2026, -$78.5 million in Q4 2025, and $138.9 million in Q3 2025.